Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia

Diabetes, Obesity and Metabolism

Volumn 18, Issue 6, 2016, Pages 628-632

  Wan Seman, W J ^a   Kori, N ^b   Rajoo, S ^a   Othman, H ^b   Mohd Noor, N ^a   Wahab, N A ^b   Sukor, N ^b   Mustafa, N ^b   Kamaruddin, N A ^b  

^a PUTRAJAYA HOSPITAL   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

dapagliflozin; hypoglycaemia; SGLT2 inhibitor; sulphonylurea

Indexed keywords

DAPAGLIFLOZIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; METFORMIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LETHARGY; MAJOR CLINICAL STUDY; MALAYSIA; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARALLEL DESIGN; POLYDIPSIA; POLYURIA; PRURITUS; RAMADAN; RANDOMIZED CONTROLLED TRIAL; RELIGION; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; ISLAM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLAM; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; YOUNG ADULT;

EID: 84995578517     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12649     Document Type: Article

References (13)

1. Al-Arouj M, Bouguerra R, Buse J et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005; 9: 2301–2311.
2. Salti I, Bénard E, Detournay B et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004; 27: 2306–2311.
3. Hassanein M, Hanif W, Malik W et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin 2011; 27: 1367–1374.
4. Al Sifri S, Basiounny A, Echtay A et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract 2011; 65: 1132–1140.
5. Halimi S, Levy M, Huet D, Quéré S, Dejager S. Experience with vildagliptin in type 2 diabetic patients fasting during Ramadan in France: insights from the VERDI Study. Diabetes Ther 2013; 4: 385–398.
6. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. A randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care 2011; 34: 2015–2022.
7. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2: e001007.
8. Del Prato S, Nauck M, Durán-Garcia S et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4 year data. Diabetes Obes Metab 2015; 17: 581–590.
9. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting Hypoglycemia in diabetes. A report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245–1249.
10. Shete A, Shaikh A, Nayeem KJ et al. Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes 2013; 4: 358–364.
11. Henry RR, Murray AV, Marmolejo MH et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446–456.
12. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223–2233.
13. Whaley JM, Mark T, Timothy PR et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012; 5: 135–148.